ReviewVaccine2026
Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?
Review in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite marked reductions in the rate of invasive pneumococcal disease (IPD) due to widespread use of penicillin prophylaxis and vaccination, individuals with sickle cell disease (SCD) remain at disproportionately high risk of pneumococcal infections. Pneumococcal conjugate vaccines (PCVs) have demonstrated improved immunogenicity over time by inducing T cell-dependent memory responses and have contributed significantly to reducing vaccine-type IPD in this population. However, persistent disease burden from non-vaccine serotypes and suboptimal antibody durability underscores the need for broader serotype coverage and a tailored immunization schedule. Until recently, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) was recommended for individuals with SCD to expand serotype protection. However, numerous studies indicate that PPSV23 has limited effectiveness in immunocompromised populations, including SCD, and may induce hyporesponsiveness when administered repeatedly or when inappropriately sequenced with PCVs. The approval of higher-valency conjugate vaccines (e.g., PCV20 and PCV21) offers promise for expanding serotype coverage while minimizing reliance on PPSV23. Nonetheless, real-world data on immunogenicity, durability, and clinical efficacy in SCD remain sparse. This review examines the intricate immunological interactions between PCVs and PPSV23 in the context of SCD, with a focus on vaccine-induced hyporesponsiveness, serotype replacement, and the evolving epidemiology of pneumococcal disease. It highlights the need for optimized evidence-based vaccination strategies and longitudinal monitoring among patients with SCD. A precision vaccination approach tailored to the unique immunological deficits of individuals with SCD will be essential to ensure sustained and comprehensive protection against pneumococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.